Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (56)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (23)
Diagnostics guidance (3)
Highly specialised technologies guidance (1)
Interventional procedures guidance (22)
Medical technologies guidance (2)
Medicines practice guidelines (3)
NICE guidelines (34)
Public health guidelines (7)
Social care guidelines (13)
Technology appraisal guidance (56)
Apply filters
Showing 1 to 56 of 56
Sort by
Date
Title
Apply sorting
Last updated date between 1/4/2016 and 30/4/2017
Remove Last updated date between 1/4/2016 and 30/4/2017 filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
TA440
26 April 2017
26 April 2017
Ixekizumab for treating moderate to severe plaque psoriasis
TA442
26 April 2017
26 April 2017
Obeticholic acid for treating primary biliary cholangitis
TA443
26 April 2017
26 April 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
TA240
14 December 2011
29 March 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
TA438
29 March 2017
29 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
TA436
22 March 2017
22 March 2017
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
TA437
22 March 2017
22 March 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal)
TA434
22 March 2017
22 March 2017
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)
TA435
22 March 2017
22 March 2017
Ustekinumab for treating active psoriatic arthritis
TA340
4 June 2015
3 March 2017
Ustekinumab for the treatment of adults with moderate to severe psoriasis
TA180
23 September 2009
3 March 2017
Everolimus for advanced renal cell carcinoma after previous treatment
TA432
22 February 2017
22 February 2017
Apremilast for treating active psoriatic arthritis
TA433
22 February 2017
22 February 2017
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
TA429
25 January 2017
25 January 2017
Sofosbuvir–velpatasvir for treating chronic hepatitis C
TA430
25 January 2017
25 January 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
TA427
11 January 2017
11 January 2017
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
TA421
21 December 2016
21 December 2016
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
TA422
21 December 2016
21 December 2016
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
TA423
21 December 2016
21 December 2016
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
TA424
21 December 2016
21 December 2016
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
TA425
21 December 2016
21 December 2016
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
TA426
21 December 2016
21 December 2016
Ticagrelor for preventing atherothrombotic events after myocardial infarction
TA420
14 December 2016
14 December 2016
Dapagliflozin in combination therapy for treating type 2 diabetes
TA288
26 June 2013
23 November 2016
Nivolumab for previously treated advanced renal cell carcinoma
TA417
23 November 2016
23 November 2016
Dapagliflozin in triple therapy for treating type 2 diabetes
TA418
23 November 2016
23 November 2016
Apremilast for treating moderate to severe plaque psoriasis
TA419
23 November 2016
23 November 2016
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
TA415
26 October 2016
26 October 2016
Elbasvir–grazoprevir for treating chronic hepatitis C
TA413
26 October 2016
26 October 2016
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
TA414
26 October 2016
26 October 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
TA411
28 September 2016
28 September 2016
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
TA412
28 September 2016
28 September 2016
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
TA406
28 September 2016
28 September 2016
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
TA407
28 September 2016
28 September 2016
Pegaspargase for treating acute lymphoblastic leukaemia
TA408
28 September 2016
28 September 2016
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
TA409
28 September 2016
28 September 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma
TA410
28 September 2016
28 September 2016
Bosutinib for previously treated chronic myeloid leukaemia
TA401
24 August 2016
24 August 2016
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
TA402
24 August 2016
24 August 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
TA403
24 August 2016
24 August 2016
Degarelix for treating advanced hormone-dependent prostate cancer
TA404
24 August 2016
24 August 2016
Trifluridine–tipiracil for previously treated metastatic colorectal cancer
TA405
24 August 2016
24 August 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
TA391
25 May 2016
24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA259
27 June 2012
27 July 2016
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
TA398
27 July 2016
27 July 2016
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
TA399
27 July 2016
27 July 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma
TA400
27 July 2016
27 July 2016
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
TA387
27 April 2016
27 July 2016
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA393
22 June 2016
22 June 2016
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA394
22 June 2016
22 June 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
TA395
22 June 2016
22 June 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
TA396
22 June 2016
22 June 2016
Adalimumab for treating moderate to severe hidradenitis suppurativa
TA392
22 June 2016
22 June 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
TA390
25 May 2016
25 May 2016
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
TA388
27 April 2016
27 April 2016
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
TA389
27 April 2016
27 April 2016
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top